|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/337 | |
| A61K 31/475 | |||
| A61K 31/519 | |||
| A61K 38/18 | |||
| A61K 45/06 | |||
| A61P 35/00 | |||
| A61K 39/395 | |||
| A61K 31/4745 | |||
| A61K 31/513 | |||
| A61K 31/555 | |||
| A61K 31/704 | |||
| A61K 31/7048 | |||
| A61K 33/24 | |||
| A61K 38/17 | |||
| C07K 19/00 | |||
| C07K 14/71 |
| (11) | Number of the document | 2640377 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11784918.2 |
| Date of filing the European patent application | 2011-11-14 | |
| (97) | Date of publication of the European application | 2013-09-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-12-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/060666 |
| Date | 2011-11-14 |
| (87) | Number | WO 2012/068032 |
| Date | 2012-05-24 |
| (30) | Number | Date | Country code |
| 413940 P | 2010-11-15 | US | |
| 421462 P | 2010-12-09 | US |
| (72) |
LONG, Li, US
BRENNAN, Thomas, US
|
| (73) |
Five Prime Therapeutics, Inc.,
111 Oyster Point Boulevard, South San Francisco, CA 94080,
US
|
| (54) | FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES |
| FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES |